Ophthalmology Activities
Real-World Data on Neovascular Age-Related Macular Degeneration: Preserving Vision Acuity While Decreasing Injection Burden of Anti-VEGF Treatments
0290-0000-20-324-H01-P
This activity will focus on the appropriate consideration of emerging therapies to treat neovascular AMD, factors that contribute to decreasing the disease burden, and use of best practices in cost management.
1.50
Wet Age-Related Macular Degeneration: Examining Clinical and Economic Data
0290-0000-20-154-H01-P
This activity will explore extended dosing schedules of anti-VEGF biologics as well as the pharmacist’s role in promoting strategies for early and aggressive treatment to improve outcomes for patients with wet AMD.
1.50
Wet Age-Related Macular Degeneration: Advances in the Treatment Landscape
0290-0000-20-120-H01-P
This activity features a retina specialist and managed care expert and will review the pathophysiology and burden of wet AMD, advances in diagnosis and monitoring, current and emerging therapies, economic considerations, and management strategies.
1.50
An American Journal of Managed Care Supplement: Improving Treatment Strategies for Wet Age-Related Macular Degeneration
0290-0000-20-061-H01-P
This activity will enable managed care pharmacists to have a better understanding of new treatment modalities and strategies to optimize treatment in neovascular AMD.
2.00